New drug delivery system to improve cancer treatment

Published: 17-Mar-2011
Drug Delivery Research & Development Pharmaceutical

Gold nanoparticles use DNA to deliver anti-cancer drug

Scientists at Syracuse University's Chemistry Department in New York, US have created a new drug delivery system that is expected to advance the effectiveness of cancer drugs. It uses gold nanoparticles with attached DNA that binds to anti-cancer drug, Doxorubicin (DOX).

Preliminary tests indicate that this delivery device has the potential to improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast, bone marrow, thyroid, bladder, ovary, small cell lung and several others.

‘The possibilities of this new system are really exciting,’ said Professor James Dabrowiak at Syracuse University. ‘It would be easy to add to the device molecules that have the ability to target cancer cells. Another possibility is using light excitation to release high concentrations of an anti-tumour drug directly within the tumour.’

These and other upgrades could enable doctors to focus chemotherapy more tightly on cancer cells and reduce side effects on healthy cells in other parts of the body.

A key element of the system is that the DNA attached to the gold particles is engineered to bind to the DOX drug. Studies show that DOX can be transferred by diffusion to a receptor DNA molecule.

The gold nanoparticles have an average diameter of only 15.5nm or a few billionths of a metre. A single nanoparticle presents more than 100 DOX sites and that, when multiplied by millions of particles, could create a massive assault on a tumour, the researchers have found.

‘We believe this work can bring significant gains in the effectiveness of chemotherapy treatments,’ said Mathew Maye, Assistant Professor of Chemistry at Syracuse University and co-inventor of the delivery system. ‘We still have work to do but this advance opens a promising new field of investigation that can lead to important new clinical tools.’

The US FDA has already approved DOX. Other such drugs may be deployed using this system simply by engineering the DNA to bind to a different drug molecule.

The Syracuse researchers are continuing investigations to check the toxicity of the system. They will also explore ‘smart’ particles capable of attaching to cancer cells and responding to triggers that will activate drug release.

The work of the Syracuse team is published in a February 2011 issue of ChemComm, published by the Royal Society of Chemistry.



See more

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

Read more
This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs

Trending Articles

  1. Johnson & Johnson files FDA application for IMAAVY in wAIHA Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy
  3. Horizon Europe 2025 grant backs Phase II trial of HER-096 for Parkinson’s disease Herantis Pharma has secured selection for €8m in non-dilutive funding under Horizon Europe to advance a Phase II proof-of-concept study of its subcutaneously delivered Parkinson’s therapy candidate HER-096
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    From injection to ingestion: can yeast make vaccines more accessible? As global vaccination coverage declines and distribution challenges persist, researchers are exploring edible yeast-based vaccines as a simpler, more scalable alternative to injections
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    AI might find the molecule, but delivery decides whether it becomes a medicine As the pharmaceutical industry scales AI-driven discovery at unprecedented speed, will the early integration of formulation and manufacturability determine which computationally promising molecules become deliverable medicines?

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

AI might find the molecule, but delivery decides whether it becomes a medicine

As the pharmaceutical industry scales AI-driven discovery at unprecedented speed, will the early integration of formulation and manufacturability determine which computationally promising molecules become deliverable medicines?
Subscribe now